Prasco to market authorized generic form of Evista

CINCINNATI — Prasco Labs on Tuesday announced that it has signed a marketing and distribution agreement with Eli Lilly and Co. to market the authorized generic version of Evista (raloxifene hydrochloride tablets), 60 mg strength, in the United States.



Evista is an estrogen agonist/antagonist used for the treatment and prevention of osteoporosis in postmenopausal women, the company said. It's also used for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women who are at high risk for invasive breast cancer.



"Prasco continues to demonstrate our passion to bring high-quality, low-cost prescription drugs to consumers," said Prasco president and COO, David Vucurevich, R.Ph. "Evista represents our third Eli Lilly and Company Authorized Generic product launched, and we are very pleased to broaden that relationship.



Prasco will start shipping the product immediately. Financial terms of the agreement were not disclosed.